Paul Scorer

733 total citations
19 papers, 553 citations indexed

About

Paul Scorer is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Paul Scorer has authored 19 papers receiving a total of 553 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 5 papers in Cancer Research and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Paul Scorer's work include Cancer Immunotherapy and Biomarkers (13 papers), Cancer Genomics and Diagnostics (5 papers) and CAR-T cell therapy research (4 papers). Paul Scorer is often cited by papers focused on Cancer Immunotherapy and Biomarkers (13 papers), Cancer Genomics and Diagnostics (5 papers) and CAR-T cell therapy research (4 papers). Paul Scorer collaborates with scholars based in United Kingdom, United States and Spain. Paul Scorer's co-authors include Craig Barker, Marietta Scott, Jill Walker, M. Ratcliffe, Marlon C. Rebelatto, Alan Sharpe, Hytham Al‐Masri, Anita Midha, Michel E. Vandenberghe and Anne-Marie Boothman and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Paul Scorer

18 papers receiving 542 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Paul Scorer United Kingdom 12 440 221 97 97 79 19 553
Kensei Nakata Japan 14 232 0.5× 125 0.6× 59 0.6× 52 0.5× 129 1.6× 30 506
Chanchal Goswami India 11 395 0.9× 297 1.3× 45 0.5× 25 0.3× 65 0.8× 21 563
U. Matulonis United States 9 342 0.8× 252 1.1× 46 0.5× 126 1.3× 57 0.7× 33 596
Pritesh Trivedi United Kingdom 11 189 0.4× 83 0.4× 88 0.9× 97 1.0× 39 0.5× 20 402
Kristie Lawhorn United States 6 294 0.7× 175 0.8× 62 0.6× 30 0.3× 72 0.9× 11 459
J.M. del Campo Spain 10 373 0.8× 217 1.0× 72 0.7× 28 0.3× 155 2.0× 17 639
James Sun United States 8 496 1.1× 293 1.3× 295 3.0× 39 0.4× 86 1.1× 16 715
Zaid Abdel Rahman United States 9 350 0.8× 82 0.4× 120 1.2× 126 1.3× 41 0.5× 38 570
Pieter‐Jan van Dam Belgium 16 335 0.8× 209 0.9× 278 2.9× 89 0.9× 68 0.9× 37 684
Hongfei Gao China 14 260 0.6× 174 0.8× 203 2.1× 41 0.4× 96 1.2× 52 536

Countries citing papers authored by Paul Scorer

Since Specialization
Citations

This map shows the geographic impact of Paul Scorer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Scorer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Scorer more than expected).

Fields of papers citing papers by Paul Scorer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Scorer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Scorer. The network helps show where Paul Scorer may publish in the future.

Co-authorship network of co-authors of Paul Scorer

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Scorer. A scholar is included among the top collaborators of Paul Scorer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Scorer. Paul Scorer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Scott, Marietta, Michel E. Vandenberghe, Paul Scorer, Anne-Marie Boothman, & Craig Barker. (2021). Prevalence of HER2 low in breast cancer subtypes using the VENTANA anti-HER2/neu (4B5) assay.. Journal of Clinical Oncology. 39(15_suppl). 1021–1021. 35 indexed citations
2.
3.
4.
Zając, M, Marietta Scott, M. Ratcliffe, et al.. (2019). Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma. Diagnostic Pathology. 14(1). 99–99. 38 indexed citations
5.
Scott, Marietta, et al.. (2019). Comparison of patient populations identified by different PD-L1 assays in in triple-negative breast cancer (TNBC). Annals of Oncology. 30. iii4–iii4. 24 indexed citations
6.
Scorer, Paul, Marietta Scott, M. Ratcliffe, et al.. (2018). Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay. Diagnostic Pathology. 13(1). 47–47. 22 indexed citations
7.
Walker, Jill, Jiabu Ye, Marietta Scott, et al.. (2018). Impact of different programmed cell death ligand-1 (PD-L1) expression algorithms on patient selection and durvalumab efficacy in urothelial carcinoma (UC). Annals of Oncology. 29. viii322–viii322. 2 indexed citations
8.
Ratcliffe, M., Alan Sharpe, Anita Midha, et al.. (2017). Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non–Small Cell Lung Cancer. Clinical Cancer Research. 23(14). 3585–3591. 237 indexed citations
9.
Stokes, Michael E., Sophie Wildsmith, Maria Secrier, et al.. (2017). Relationship between PD-L1 expression and survival in head and neck squamous cell carcinoma (HNSCC) patients (pts). Annals of Oncology. 28. v375–v375. 5 indexed citations
10.
Ratcliffe, M., Alan Sharpe, Craig Barker, et al.. (2017). Correction to: Abstracts. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 472(2). 301–301. 1 indexed citations
11.
Scott, Marietta, M. Ratcliffe, Alan Sharpe, et al.. (2017). Concordance of tumor and immune cell staining with Ventana SP142, Ventana SP263, Dako 28-8 and Dako 22C3 PD-L1 tests in NSCLC patient samples.. Journal of Clinical Oncology. 35(7_suppl). 7–7. 6 indexed citations
12.
Scott, Marietta, M. Ratcliffe, Alan Sharpe, et al.. (2017). Concordance of tumor cell (TC) and immune cell (IC) staining with Ventana SP142, Ventana SP263, Dako 28-8 and Dako 22C3 PD-L1 IHC tests in NSCLC patient samples.. Journal of Clinical Oncology. 35(15_suppl). e14503–e14503. 5 indexed citations
13.
Scott, Marietta, Paul Scorer, M. Ratcliffe, et al.. (2017). Assessment of heterogeneity of PD-L1 expression in NSCLC, HNSCC, and UC with Ventana SP263 assay.. Journal of Clinical Oncology. 35(15_suppl). e14502–e14502. 9 indexed citations
14.
Ratcliffe, M., Alan Sharpe, Marlon C. Rebelatto, et al.. (2016). A comparative study of PD-L1 diagnostic assays in squamous cell carcinoma of the head and neck (SCCHN). Annals of Oncology. 27. vi330–vi330. 14 indexed citations
15.
Ratcliffe, M., Alan Sharpe, Anita Midha, et al.. (2016). Abstract LB-094: A comparative study of PD-L1 diagnostic assays and the classification of patients as PD-L1 positive and PD-L1 negative. Cancer Research. 76(14_Supplement). LB–94. 18 indexed citations
16.
Happerfield, Lisa, Gary McIntosh, Mark Rees, et al.. (2009). Phospho‐STAT5 and phospho‐Akt expression in chronic myeloproliferative neoplasms. British Journal of Haematology. 147(4). 495–506. 56 indexed citations
17.
Girdler, Fiona, David Browell, W.J. Cunliffe, et al.. (2001). Use of the monoclonal antibody DAKO-ER? (8D5-1) to measure oestrogen receptor beta in breast cancer cells. Cytometry. 45(1). 65–72. 15 indexed citations
18.
Ansink, Anca C., Paul Cross, Paul Scorer, Alberto Lopes, & John Monaghan. (1997). The hormonal receptor status of uterine carcinosarcomas (mixed müllerian tumours): an immunohistochemical study.. Journal of Clinical Pathology. 50(4). 328–331. 26 indexed citations
19.
Scorer, Paul. (1989). The Equalization of Channel Noise Visibility in Television. SMPTE Journal. 98(8). 563–567.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kensei Nakata Breakdown of academic impact, for papers by Chanchal Goswami Breakdown of academic impact, for papers by U. Matulonis Breakdown of academic impact, for papers by Pritesh Trivedi Breakdown of academic impact, for papers by Kristie Lawhorn Breakdown of academic impact, for papers by J.M. del Campo Breakdown of academic impact, for papers by James Sun Breakdown of academic impact, for papers by Zaid Abdel Rahman Breakdown of academic impact, for papers by Pieter‐Jan van Dam Breakdown of academic impact, for papers by Hongfei Gao
Rankless by CCL
2026